Biotech Medics Ne Stock Net Income
| BMCS Stock | USD 0.01 0.0003 3.95% |
As of the 29th of January, Biotech Medics shows the Risk Adjusted Performance of 0.0421, mean deviation of 3.69, and Downside Deviation of 18.44. Biotech Medics Ne technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Biotech Medics Ne coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Biotech Medics Ne is priced correctly, providing market reflects its regular price of 0.0079 per share. As Biotech Medics Ne appears to be a penny stock we also recommend to validate its total risk alpha numbers.
Biotech Medics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Biotech Medics' valuation are provided below:Biotech Medics Ne does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Biotech |
Biotech Medics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Biotech Medics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Biotech Medics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Biotech Medics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Biotech Medics Ne or generate 0.0% return on investment in Biotech Medics over 90 days. Biotech Medics is related to or competes with Procyon. BioTech Medics, Inc. operates as a medical-based holding company More
Biotech Medics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Biotech Medics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Biotech Medics Ne upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 18.44 | |||
| Information Ratio | 0.0382 | |||
| Maximum Drawdown | 94.28 | |||
| Value At Risk | (3.66) | |||
| Potential Upside | 3.95 |
Biotech Medics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biotech Medics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Biotech Medics' standard deviation. In reality, there are many statistical measures that can use Biotech Medics historical prices to predict the future Biotech Medics' volatility.| Risk Adjusted Performance | 0.0421 | |||
| Jensen Alpha | 0.4272 | |||
| Total Risk Alpha | (0.54) | |||
| Sortino Ratio | 0.0249 | |||
| Treynor Ratio | 0.3496 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biotech Medics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Biotech Medics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0421 | |||
| Market Risk Adjusted Performance | 0.3596 | |||
| Mean Deviation | 3.69 | |||
| Semi Deviation | 6.69 | |||
| Downside Deviation | 18.44 | |||
| Coefficient Of Variation | 2248.71 | |||
| Standard Deviation | 12.02 | |||
| Variance | 144.5 | |||
| Information Ratio | 0.0382 | |||
| Jensen Alpha | 0.4272 | |||
| Total Risk Alpha | (0.54) | |||
| Sortino Ratio | 0.0249 | |||
| Treynor Ratio | 0.3496 | |||
| Maximum Drawdown | 94.28 | |||
| Value At Risk | (3.66) | |||
| Potential Upside | 3.95 | |||
| Downside Variance | 340.19 | |||
| Semi Variance | 44.81 | |||
| Expected Short fall | (24.91) | |||
| Skewness | 2.48 | |||
| Kurtosis | 17.18 |
Biotech Medics Ne Backtested Returns
Biotech Medics appears to be out of control, given 3 months investment horizon. Biotech Medics Ne secures Sharpe Ratio (or Efficiency) of 0.0505, which signifies that the company had a 0.0505 % return per unit of risk over the last 3 months. By analyzing Biotech Medics' technical indicators, you can evaluate if the expected return of 0.63% is justified by implied risk. Please makes use of Biotech Medics' Mean Deviation of 3.69, downside deviation of 18.44, and Risk Adjusted Performance of 0.0421 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Biotech Medics holds a performance score of 4. The firm shows a Beta (market volatility) of 1.5, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biotech Medics will likely underperform. Please check Biotech Medics' treynor ratio and the relationship between the semi variance and relative strength index , to make a quick decision on whether Biotech Medics' price patterns will revert.
Auto-correlation | -0.16 |
Insignificant reverse predictability
Biotech Medics Ne has insignificant reverse predictability. Overlapping area represents the amount of predictability between Biotech Medics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Biotech Medics Ne price movement. The serial correlation of -0.16 indicates that over 16.0% of current Biotech Medics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.16 | |
| Spearman Rank Test | -0.39 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Biotech Medics Ne reported net income of (603,722). This is 100.18% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 100.11% higher than that of the company.
Biotech Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotech Medics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Biotech Medics could also be used in its relative valuation, which is a method of valuing Biotech Medics by comparing valuation metrics of similar companies.Biotech Medics is currently under evaluation in net income category among its peers.
Biotech Fundamentals
| Profit Margin | (1.29) % | |||
| Operating Margin | (1.24) % | |||
| Current Valuation | 9.68 M | |||
| Shares Outstanding | 172.36 M | |||
| Price To Earning | (0.47) X | |||
| Price To Sales | 3.30 X | |||
| Revenue | 469.8 K | |||
| Gross Profit | 408.14 K | |||
| EBITDA | 33.35 K | |||
| Net Income | (603.72 K) | |||
| Cash And Equivalents | 1.31 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 0.01 X | |||
| Book Value Per Share | 0.02 X | |||
| Earnings Per Share | (0) X | |||
| Beta | 3.5 | |||
| Market Capitalization | 870.4 K | |||
| Total Asset | 5.08 M | |||
| Retained Earnings | (1.75 M) | |||
| Working Capital | (1.98 M) | |||
| Current Asset | 27 K | |||
| Current Liabilities | 2.01 M | |||
| Net Asset | 5.08 M |
About Biotech Medics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotech Medics Ne's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotech Medics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotech Medics Ne based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Biotech Pink Sheet Analysis
When running Biotech Medics' price analysis, check to measure Biotech Medics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotech Medics is operating at the current time. Most of Biotech Medics' value examination focuses on studying past and present price action to predict the probability of Biotech Medics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotech Medics' price. Additionally, you may evaluate how the addition of Biotech Medics to your portfolios can decrease your overall portfolio volatility.